NDA 216793 · Janssen Biotech
Akeega
Abiraterone Acetate, Niraparib Tosylate · Oral
Priority reviewLast checked: Nov 20, 2026Latest source record: Dec 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Aug 11, 2023
Approved uses
2
Original approval plus efficacy supplements
Registered trials
415
71 Phase 3, 75 recruiting
FAERS reports
62
45 serious, 12 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 18, 2025.
AKEEGA with prednisone is indicated for the treatment of adult patients with deleterious or suspected deleterious BRCA2 -mutated ( BRCA2 m) metastatic castration-sensitive prostate cancer (mCSPC). AKEEGA with prednisone is indicated for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for AKEEGA [see Dosage and Administration (2.1) ] . AKEEGA is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with: deleterious or suspected deleterious BRCA2 -mutated ( BRCA2 m) metastatic castration-sensitive prostate cancer (mCSPC). deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for AKEEGA. ( 1 , 2.1 )
Mechanism: Niraparib is an inhibitor of PARP enzymes, including PARP-1 and PARP-2, that play a role in DNA repair. In vitro studies have shown that niraparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis, and cell death. Increased niraparib‑induced cytotoxicity was observed in tumor cell lines with or without deficiencies in BRCA1/2 . Niraparib decreased tumor growth in mouse xenograft models of human cancer cell lines with deficiencies in BRCA1/2 and in human patient‑derived xenograft tumor models...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 12, 2025 Supplement 1 · Efficacy · priority review LetterLetterLabel
- Aug 11, 2023 Original approval · Type 4 - New Combination · priority review LabelLetterReview
2 products under this application
- AKEEGA · ABIRATERONE ACETATE 500MG; NIRAPARIB TOSYLATE EQ 100MG BASE · TABLET, ORAL · Prescription
- AKEEGA · ABIRATERONE ACETATE 500MG; NIRAPARIB TOSYLATE EQ 50MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Abiraterone" as an intervention, any sponsor and status, largest first.
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyPivotal-lookingActive, not recruiting
Medical Research CouncilGovernment (non-federal)
NCT00268476 · 11,992 participants · Start Jul 8, 2005 · Primary completion Mar 2026
Drug: Celecoxib; Docetaxel and 7 more · For: Prostate Cancer
Sites: Lausanne, Switzerland; Winterthur, Switzerland; Chur, Switzerland · 120 sites in all
- Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyPivotal-lookingEnrolling by invitation
ExelixisIndustry
NCT07620574 · 5,000 participants (planned) · Start Jul 30, 2026 · Primary completion May 31, 2030
Drug: Cabozantinib; Zanzalintinib and 5 more · For: Cancer; Renal Cell Carcinoma (RCC); Pancreatic Neuroendocrine Tumors (pNET) and 6 more
Sites: Bay Shore, New York; Kettering, Ohio; Memphis, Tennessee · 4 sites in all
- A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate CancerPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT06320067 · 3,360 participants (planned) · Start Jun 11, 2024 · Primary completion Apr 2031
Drug: Androgen Deprivation Therapy (ADT); Androgen Receptor Signalling Inhibitor (ARPI) and 1 more · For: Prostate Cancer Metastatic
Sites: Barnsley, United Kingdom; Cambridge, United Kingdom; Exeter, United Kingdom · 18 sites in all
- Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06120491 · 1,898 participants · Start Nov 21, 2023 · Primary completion Sep 30, 2027
Drug: Saruparib; Placebo and 3 more · For: Metastatic Castration-Sensitive Prostate Cancer
Sites: Chandler, Arizona; Gilbert, Arizona; Phoenix, Arizona · 322 sites in all
- Intermittent Androgen Deprivation Therapy in the Era of AR Pathway InhibitorsPivotal-lookingRecruiting
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT05974774 · 1,600 participants (planned) · Start May 23, 2025 · Primary completion May 23, 2035
Drug: iMAB; cMAB · For: Prostate Cancer
Sites: Copenhagen, Denmark; Caen, France; Grenoble, France · 9 sites in all
- Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate CancerPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT07751133 · 1,500 participants (planned) · Start Aug 28, 2026 · Primary completion Aug 1, 2029
Drug: Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy · For: Prostate Cancer; mHSPC; mCRPC
Sites: Huddersfield, United Kingdom; Manchester, United Kingdom; Sutton, United Kingdom · 4 sites in all
- Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07711002 · 1,330 participants (planned) · Start Sep 15, 2026 · Primary completion May 30, 2031
Drug: Saruparib; Enzalutamide and 2 more · For: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Sites: Hot Springs, Arkansas; Springdale, Arkansas; Beverly Hills, California · 210 sites in all
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06136650 · 1,314 participants (planned) · Start Dec 18, 2023 · Primary completion May 10, 2028
Drug: Opevesostat; Dexamethasone and 5 more · For: Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms
Sites: Tucson, Arizona; Irvine, California; Los Angeles, California · 330 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use6
- constipation4
- decreased appetite4
- fatigue4
- nausea4
- product ineffective for unapproved use4
- prostatic specific antigen increased4
- abdominal pain upper3
- blood pressure increased3
- death3
- dizziness3
- drug ineffective3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 25 |
| 2025 | 16 |
| 2026 | 21 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Akeega (Niraparib/Abiraterone)
2024 spending
$5.7M
Beneficiaries
74
317 claims
Per beneficiary
$77,684
$308.19 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $566,563 |
| 2024 | $5,748,652 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Olaparib for Metastatic Castration-Resistant Prostate Cancer.
de Bono J, Mateo J, Fizazi K, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
- Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G, Murphy L, Clarke NW, et al. · Lancet 2022 · Meta-Analysis
- Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2ߙ×ߙ2 factorial design.
Fizazi K, Foulon S, Carles J, et al. · Lancet 2022 · Clinical Trial, Phase III, Multicenter Study
- Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
Chi KN, Rathkopf D, Smith MR, et al. · J Clin Oncol 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study.
Fizazi K, Clarke NW, De Santis M, et al. · Ann Oncol 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer.
Fizazi K, Chi KN, Shore ND, et al. · Ann Oncol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.